NovoCure Ltd NVCR revenue by segment, product and geography
In its fiscal year ending 2025-12-31, NovoCure Ltd reported revenue across 7 geographies; the largest, United States, was $386M (-1.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- United States$386Mshare n/a-1.6% yoy
- International Markets$250Mshare n/a+27.7% yoy
- Germany$79.4Mshare n/a+21.7% yoy
- France$76.2Mshare n/a+36.7% yoy
- Other International Markets$56.9Mshare n/a+34.0% yoy
- Japan$37.8Mshare n/a+16.0% yoy
- China$19.4Mshare n/a+11.8% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$103Mshare n/ano prior
- International Markets$74.7Mshare n/ano prior
- Germany$23.3Mshare n/ano prior
- France$21.3Mshare n/ano prior
- Other International Markets$18.2Mshare n/ano prior
- Japan$11.8Mshare n/ano prior
- +1 more member in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.